Kobayashi Pharmaceutical Mid-Year Net Profit Falls 64.1% to ¥1.1 Billion on Ad Resumption, Raw Material Costs
Kobayashi Pharmaceutical posted a 64.1% year-on-year drop in net profit to ¥1.1 billion for the six months ended June 2026, compared with the same period in 2024, while sales rose 2.5% to ¥70.7 billion. The company resumed advertising in July 2025 after halting it due to the red yeast supplement health issue, lifting costs. As of end-July 2026, compensation had been extended to 520 individuals, of whom 380 had received payments.
Kobayashi Pharmaceutical announced on the 6th its consolidated results for the six months ended June 2026, showing sales of ¥70.7 billion, up 2.5% from the same period in 2024, and net profit of ¥1.1 billion, down 64.1% year on year. Advertising, which had been suspended due to the health hazards linked to its red yeast supplements, fully resumed in July 2025, leading to higher related expenses.
The company disclosed the health issue in March 2024. As of the end of July 2026, compensation had been offered to 520 individuals, of whom 380 had already received payments for solatium and medical expenses.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is negative for Nutrition & Supplements, with intensity 30/100 and 60% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.